心力衰竭中的SGLT2抑制剂：超出血糖控制：欧洲心脏病学会心力衰竭协会立场文件

2021-11-02 欧洲心脏病学会 Eur J Heart Fail . 2020 Sep;22(9):1495-1503

尽管治疗取得了进展，但心力衰竭 (HF) 很常见并且与不良预后相关。在过去十年中，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在 2 型糖尿病患者中的心血管结局试验表明，三种 SGLT2 抑制

中文标题：

英文标题：

Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

发布机构：

欧洲心脏病学会

发布日期：

2021-11-02

简要介绍：

尽管治疗取得了进展，但心力衰竭 (HF) 很常见并且与不良预后相关。在过去十年中，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在 2 型糖尿病患者中的心血管结局试验表明，三种 SGLT2 抑制剂（恩格列净、卡格列净和达格列净）在减少 HF 住院方面具有有益作用。最近，达格列净降低了左心室射血分数降低的慢性心衰患者心衰恶化或心血管原因死亡的风险，无论是否患有 2 型糖尿病。许多针对左心室射血分数降低和/或保留的 HF 患者的额外试验正在进行中和/或即将报告。本立场文件总结了最近的临床试验证据，并讨论了 SGLT2 抑制剂在治疗 HF 中的作用，等待在不同 HF 患者人群中进行的试验结果。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=578b21c0022a93b4, title=心力衰竭中的SGLT2抑制剂：超出血糖控制：欧洲心脏病学会心力衰竭协会立场文件 , enTitle=Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology, guiderFrom=Eur J Heart Fail . 2020 Sep;22(9):1495-1503, authorId=0, author=, summary=尽管治疗取得了进展，但心力衰竭 (HF) 很常见并且与不良预后相关。在过去十年中，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在 2 型糖尿病患者中的心血管结局试验表明，三种 SGLT2 抑制, cover=, journalId=0, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会，会员超过70000人、提供更新指南、调查数据、组织学术会议，ESC年会是心血管领域最大的会议。下设5个分会（超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会）。提供指南较全面，按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Tue Nov 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=尽管治疗取得了进展，但心力衰竭 (HF) 很常见并且与不良预后相关。 在过去十年中，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在 2 型糖尿病患者中的心血管结局试验表明，三种 SGLT2 抑制剂（恩格列净、卡格列净和达格列净）在减少 HF 住院方面具有有益作用。 最近，达格列净降低了左心室射血分数降低的慢性心衰患者心衰恶化或心血管原因死亡的风险，无论是否患有 2 型糖尿病。 许多针对左心室射血分数降低和/或保留的 HF 患者的额外试验正在进行中和/或即将报告。 本立场文件总结了最近的临床试验证据，并讨论了 SGLT2 抑制剂在治疗 HF 中的作用，等待在不同 HF 患者人群中进行的试验结果。, tagList=[TagDto(tagId=335, tagName=心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2241, appHits=139, showAppHits=0, pcHits=390, showPcHits=2102, likes=0, shares=9, comments=7, approvalStatus=1, publishedTime=Tue Nov 02 08:16:35 CST 2021, publishedTimeString=2021-11-02, pcVisible=1, appVisible=1, editorId=4754896, editor=小小医者, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=小小医者, createdTime=Mon Nov 01 23:36:51 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 18:55:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=1.pdf)])

1.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1066430, encodeId=c44310664308d, content=达格列净在心衰患者中的证据越来越多<a href='/topic/show?id=f5cb5192610' target=_blank style='color:#2F92EE;'>#心衰#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=51926, encryptionId=f5cb5192610, topicName=心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:32 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074185, encodeId=2d3710e4185b4, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:04:39 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066678, encodeId=9e9510666e854, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211017/06579159c2b1435d8909b4807c99bd19/c758f2fa7e19486bac3bc3b90f0e40e0.jpg, createdBy=65493672398, createdName=勇往直前称, createdTime=Wed Nov 03 19:52:48 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066431, encodeId=0f02106643159, content=好好学习<a href='/topic/show?id=d91a5192ec3' target=_blank style='color:#2F92EE;'>#心衰、ESC、心血管#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51927, encryptionId=d91a5192ec3, topicName=心衰、ESC、心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:57 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
2021-11-02 1e1ac4a1m23(暂无匿称)

达格列净在心衰患者中的证据越来越多#心衰#

139 1

展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=1066430, encodeId=c44310664308d, content=达格列净在心衰患者中的证据越来越多<a href='/topic/show?id=f5cb5192610' target=_blank style='color:#2F92EE;'>#心衰#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=51926, encryptionId=f5cb5192610, topicName=心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:32 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074185, encodeId=2d3710e4185b4, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:04:39 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066678, encodeId=9e9510666e854, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211017/06579159c2b1435d8909b4807c99bd19/c758f2fa7e19486bac3bc3b90f0e40e0.jpg, createdBy=65493672398, createdName=勇往直前称, createdTime=Wed Nov 03 19:52:48 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066431, encodeId=0f02106643159, content=好好学习<a href='/topic/show?id=d91a5192ec3' target=_blank style='color:#2F92EE;'>#心衰、ESC、心血管#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51927, encryptionId=d91a5192ec3, topicName=心衰、ESC、心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:57 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
2021-11-26 H8888888

不错学习了

60 0
[GetPortalCommentsPageByObjectIdResponse(id=1066430, encodeId=c44310664308d, content=达格列净在心衰患者中的证据越来越多<a href='/topic/show?id=f5cb5192610' target=_blank style='color:#2F92EE;'>#心衰#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=51926, encryptionId=f5cb5192610, topicName=心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:32 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074185, encodeId=2d3710e4185b4, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:04:39 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066678, encodeId=9e9510666e854, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211017/06579159c2b1435d8909b4807c99bd19/c758f2fa7e19486bac3bc3b90f0e40e0.jpg, createdBy=65493672398, createdName=勇往直前称, createdTime=Wed Nov 03 19:52:48 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066431, encodeId=0f02106643159, content=好好学习<a href='/topic/show?id=d91a5192ec3' target=_blank style='color:#2F92EE;'>#心衰、ESC、心血管#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51927, encryptionId=d91a5192ec3, topicName=心衰、ESC、心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:57 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
2021-11-03 勇往直前称

好

80 0
[GetPortalCommentsPageByObjectIdResponse(id=1066430, encodeId=c44310664308d, content=达格列净在心衰患者中的证据越来越多<a href='/topic/show?id=f5cb5192610' target=_blank style='color:#2F92EE;'>#心衰#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=51926, encryptionId=f5cb5192610, topicName=心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:32 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074185, encodeId=2d3710e4185b4, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:04:39 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066678, encodeId=9e9510666e854, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211017/06579159c2b1435d8909b4807c99bd19/c758f2fa7e19486bac3bc3b90f0e40e0.jpg, createdBy=65493672398, createdName=勇往直前称, createdTime=Wed Nov 03 19:52:48 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066431, encodeId=0f02106643159, content=好好学习<a href='/topic/show?id=d91a5192ec3' target=_blank style='color:#2F92EE;'>#心衰、ESC、心血管#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51927, encryptionId=d91a5192ec3, topicName=心衰、ESC、心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdd51992964, createdName=1e1ac4a1m23(暂无匿称), createdTime=Tue Nov 02 23:36:57 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
2021-11-02 1e1ac4a1m23(暂无匿称)

好好学习#心衰、ESC、心血管#

80 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

心力衰竭中的SGLT2抑制剂：超出血糖控制：欧洲心脏病学会心力衰竭协会立场文件

相关指南

科室

工具

服务

心血管指南

心力衰竭中的SGLT2抑制剂：超出血糖控制： 欧洲心脏病学会心力衰竭协会立场文件

相关指南

科室

工具

服务

心力衰竭中的SGLT2抑制剂：超出血糖控制：欧洲心脏病学会心力衰竭协会立场文件